Market Cap | 478.44M | P/E | - | EPS this Y | -21.40% | Ern Qtrly Grth | - |
Income | -49.83M | Forward P/E | -23.32 | EPS next Y | 51.20% | 50D Avg Chg | 16.00% |
Sales | 54.14M | PEG | -0.05 | EPS past 5Y | - | 200D Avg Chg | 64.00% |
Dividend | N/A | Price/Book | 30.87 | EPS next 5Y | 127.50% | 52W High Chg | -13.00% |
Recommedations | 2.20 | Quick Ratio | 4.65 | Shares Outstanding | 25.99M | 52W Low Chg | 328.00% |
Insider Own | 0.97% | ROA | -38.98% | Shares Float | 25.05M | Beta | 1.53 |
Inst Own | 23.75% | ROE | -107.66% | Shares Shorted/Prior | 1.55M/1.62M | Price | 18.89 |
Gross Margin | 86.09% | Profit Margin | -92.04% | Avg. Volume | 296,261 | Target Price | 15.20 |
Oper. Margin | -102.69% | Earnings Date | Nov 7 | Volume | 93,726 | Change | -4.50% |
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Cantor Fitzgerald | Overweight | Aug 9, 24 |
Piper Sandler | Neutral | May 14, 24 |
Cantor Fitzgerald | Overweight | May 14, 24 |
BTIG | Neutral | Apr 11, 24 |
Piper Sandler | Overweight | Feb 23, 24 |
Cantor Fitzgerald | Overweight | Feb 23, 24 |
Cantor Fitzgerald | Overweight | Jan 19, 24 |
Cantor Fitzgerald | Overweight | Nov 21, 23 |
Piper Sandler | Overweight | Nov 10, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
CORBETT JAMES | CEO CEO | Dec 26 | Sell | 13.29 | 1,445 | 19,204 | 11,580 | 12/27/23 |
COOK JEREMY CURNOCK | Director Director | Dec 21 | Sell | 12.49 | 2,500 | 31,225 | 20,614 | 12/22/23 |
O'Toole David D | CFO CFO | Nov 30 | Buy | 10.68 | 500 | 5,340 | 16,534 | 12/04/23 |
O'Toole David D | CFO CFO | Nov 14 | Buy | 13.07 | 2,000 | 26,140 | 11,000 | 11/15/23 |
Shiroma Donna | General Counsel General Counsel | Aug 21 | Sell | 15.84 | 4,193 | 66,417 | 42,257 | 09/08/23 |
O'Toole David D | CFO CFO | Aug 16 | Buy | 17.06 | 2,000 | 34,120 | 9,000 | 08/16/23 |
O'Toole David D | CFO CFO | Aug 15 | Buy | 17.93 | 5,000 | 89,650 | 7,000 | 08/15/23 |
O'Toole David D | CFO CFO | Jun 20 | Buy | 16.15 | 1,000 | 16,150 | 2,000 | 06/21/23 |
PERRY MICHAEL S | Chief Executive Offi.. Chief Executive Officer | Sep 16 | Sell | 27.21 | 47,861 | 1,302,298 | 425,087 | 09/16/20 |